Tectonic Therapeutic, Inc. (TECX)
| Market Cap | 682.47M +65.1% |
| Revenue (ttm) | n/a |
| Net Income | -85.79M |
| EPS | -4.56 |
| Shares Out | 19.55M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 84,238 |
| Open | 33.63 |
| Previous Close | 33.98 |
| Day's Range | 33.32 - 35.03 |
| 52-Week Range | 14.39 - 39.53 |
| Beta | 0.22 |
| Analysts | Strong Buy |
| Price Target | 77.56 (+122.17%) |
| Earnings Date | Aug 6, 2026 |
About TECX
Tectonic Therapeutic, Inc., a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein coupled receptors (GPCRs). It develops GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company’s lead product is TX45, a Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone, and relaxin. It is also developing TX2100 for the treatment of hereditary hemorrhagic telangiectasia; GPC... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for TECX stock is "Strong Buy." The 12-month stock price target is $77.56, which is an increase of 122.17% from the latest price.
News
Tectonic Therapeutic Announces Second Quarter 2026 Financial Results and Recent Business Highlights
Enrollment completed in TX45 APEX Phase 2 clinical trial in patients with pulmonary hypertension associated with heart failure with preserved ejection fraction (“PH-HFpEF”) with topline results antici...
Tectonic Therapeutic Quarterly report: Q2 2026
Tectonic Therapeutic has published its Q2 2026 quarterly earnings report on August 6, 2026.
Tectonic Therapeutic Earnings release: Q2 2026
Tectonic Therapeutic released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Tectonic Therapeutic Slides: Investor presentation
Tectonic Therapeutic has posted slides in relation to its latest quarterly earnings report, which was published on August 1, 2026.
Tectonic Therapeutic completes enrollment for APEX trial
Tectonic Therapeutic (TECX) announced the completion of enrollment for the APEX trial, a 24-week Phase 2 clinical trial evaluating the safety and efficacy of TX45 in patients with pulmonary hypertensi...
Tectonic Therapeutic Completes Enrollment in TX45 APEX Phase 2 Clinical Trial in PH-HFpEF Patients
WATERTOWN, Mass., June 10, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic” or the “Company”), a clinical stage biotechnology company focused on the discovery and develop...
Tectonic Therapeutic Transcript: AGM 2026
The meeting covered board elections, auditor ratification, and executive compensation, with all proposals approved by shareholders. No questions were raised, and voting results will be filed with the SEC within four business days.
Tectonic Therapeutic upgraded to Strong Buy from Outperform at Raymond James
Raymond James analyst Martin Auster upgraded Tectonic Therapeutic (TECX) to Strong Buy from Outperform with a price target of $81, up from $76. The company offers an “uncommonly attractive opportunity...
Tectonic Therapeutic Announces First Quarter 2026 Financial Results and Recent Business Highlights
WATERTOWN, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic” or the “Company”), a clinical stage biotechnology company focused on the discovery and developm...
Tectonic Therapeutic Quarterly report: Q1 2026
Tectonic Therapeutic has published its Q1 2026 quarterly earnings report on May 7, 2026.
Tectonic Therapeutic Earnings release: Q1 2026
Tectonic Therapeutic released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Tectonic Therapeutic Slides: Investor presentation
Tectonic Therapeutic has posted slides in relation to its latest quarterly earnings report, which was published on May 7, 2026.
Tectonic Therapeutic management to meet with Piper Sandler
Meeting to be held in Boston on April 29 hosted by Piper Sandler.
Tectonic Therapeutic Proxy statement: Proxy filing
Tectonic Therapeutic filed a proxy statement on April 24, 2026, providing details for shareholder voting and corporate governance matters.
Tectonic Therapeutic Proxy statement: Proxy filing
Tectonic Therapeutic filed a proxy statement on April 24, 2026, providing details for shareholder voting and corporate governance matters.
Tectonic Therapeutic Appoints Jessica Chutter to Board of Directors
WATERTOWN, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical-stage biotechnology company focused on the discovery and development of therapeu...
Tectonic Therapeutic initiated with a Buy at Stifel
Stifel initiated coverage of Tectonic Therapeutic (TECX) with a Buy rating and $75 price target The firm thinks the risk/reward ahead of the Phase 2 APEX data due in late…
Tectonic Therapeutic Transcript: Leerink Global Healthcare Conference 2026
Two clinical programs are advancing: TX45, a long-acting relaxin for pulmonary hypertension, is differentiated by patient selection and dosing, with Phase II results expected in late 2026 or early 2027. TX2100, an anti-angiogenic agent for HHT, shows strong preclinical efficacy and safety, with Phase I data due this year. The proprietary platform supports ongoing pipeline innovation.
Tectonic Therapeutic Transcript: TD Cowen 46th Annual Health Care Conference
The session highlighted progress on two clinical programs targeting major unmet needs in pulmonary hypertension and hereditary hemorrhagic telangiectasia, with key data readouts expected in late 2024 and 2026/2027. Competitive insights and trial design refinements position the pipeline for significant impact.
Tectonic Therapeutic Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
WATERTOWN, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical stage biotechnology company focused on the discovery and development of therapeut...
Tectonic Therapeutic Earnings release: Q4 2025
Tectonic Therapeutic released its Q4 2025 earnings on February 26, 2026, summarizing the period's financial results.
Tectonic Therapeutic Annual report: Q4 2025
Tectonic Therapeutic has published its Q4 2025 annual report on February 26, 2026.
Tectonic Therapeutic Transcript: KOL event
TX2100 is a first-in-class APJ antagonist targeting HHT, aiming to address a major unmet need with a differentiated, pathology-biased anti-angiogenic mechanism. Robust preclinical efficacy and safety data support ongoing clinical trials, with a focus on improving epistaxis and expanding to related disorders.
Tectonic Therapeutic Slides: KOL event
Tectonic Therapeutic has posted slides in relation to its latest quarterly earnings report, which was published on February 24, 2026.
Tectonic Therapeutic chair Terry McGuire to retire, Francois Nader to succeed
Tectonic Therapeutic (TECX) announced it has appointed Francois Nader as an independent director to its board of directors, effective April 1, at which time he will also assume the role…